Post-grant proceedings: shaping the biotech landscape

In March 2010, the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated pathway for licensing biosimilars and a 12-year exclusivity period for first licensed biologics. Shortly after, the America Invents Act (AIA) provided multiple changes to the patent system and established a variety of post-grant proceedings. Notably, the AIA established post-grant review (PGR) proceedings and inter partes review (IPR) proceedings.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Bausch reaches deal with competitor over IBS drug generic

7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.

Americas

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

1 April 2026 After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.

Americas

CRISPR priority feud ends at USPTO as board reaches decision

30 March 2026 A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.